Offering smokers a taster session at an NHS Stop Smoking Service and explaining their personal risk of developing smoking-related diseases doubles their likelihood of attending a stop smoking course.
Community pharmacists are widely recognised as an under-utilised resource within the NHS, in spite of their skills and experience, and the accessibility of their premises. In recent years, community pharmacists have demonstrated the value of the clinical services they offer, particularly in the prevention of cardiovascular disease (CVD).
In 2017 the University of Sheffield was commissioned by Public Health England (PHE) to develop a new return on investment (ROI) tool for cardiovascular disease (CVD) prevention, to be used by national and local decision-makers. The tool focuses on prevention of CVD in six key high-risk groups, identified through the NHS RightCare pathway as being currently underdiagnosed and insufficiently well managed. This includes patients with hypertension, diabetes (type 1 and type 2), non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol (the latter including patients with a QRISK2 score ≥ 10% or familial hypercholesterolaemia).
Chronic Obstructive Pulmonary Disease (COPD) has a major impact on the health and quality of life of patients and there is often co-morbidity with cardiovascular disease. Well planned and structured training for the primary care team could have a major impact on outcomes.
A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.